US20060129138A1 - Drug delivery system - Google Patents

Drug delivery system Download PDF

Info

Publication number
US20060129138A1
US20060129138A1 US11/265,724 US26572405A US2006129138A1 US 20060129138 A1 US20060129138 A1 US 20060129138A1 US 26572405 A US26572405 A US 26572405A US 2006129138 A1 US2006129138 A1 US 2006129138A1
Authority
US
United States
Prior art keywords
drug
drug delivery
delivery device
flow channel
reservoir
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/265,724
Inventor
Avtar Nat
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Standard Biotools Corp
Original Assignee
Fluidigm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fluidigm Corp filed Critical Fluidigm Corp
Priority to US11/265,724 priority Critical patent/US20060129138A1/en
Publication of US20060129138A1 publication Critical patent/US20060129138A1/en
Assigned to FLUIDIGM CORPORATION - A DELAWARE CORPORATION reassignment FLUIDIGM CORPORATION - A DELAWARE CORPORATION REINCORPORATION ASSIGNMENT Assignors: FLUIDIGM CORPORATION - A CALIFORNIA CORPORATION
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T137/00—Fluid handling
    • Y10T137/8593—Systems
    • Y10T137/87249—Multiple inlet with multiple outlet
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T137/00—Fluid handling
    • Y10T137/8593—Systems
    • Y10T137/87917—Flow path with serial valves and/or closures
    • Y10T137/88062—Coaxial oppositely directed seats

Definitions

  • An advantage of having a collapsible drug reservoir is that, as the drug is pumped out of the reservoir (by the present microfabricated pump/vale system), a negative pressure is not created in the drug reservoir.
  • the drug reservoir and micro flow channels are created as an integrated, monolithic structure using soft lithography front any of the elastomers that are compatible with a specific drug, and according to any of the systems set forth in U.S. Patent Application Ser. No. 60/186856, filed Mar. 3, 2000; 60/147199, filed Aug. 3, 1999; 60/141503, filed Jun. 28, 1999 and Attorney Docket No. 20174-000230, filed Jun. 27, 2000.
  • the delivery end of the micro channels may be terminated with any suitable valve structure, for example a duck bill narrow diameter valve or a flap valve. These valves will normally remain closed and will open under the fluid pressure of the drug during expulsion from the micro flow channels.
  • a duck bill narrow diameter valve or a flap valve These valves will normally remain closed and will open under the fluid pressure of the drug during expulsion from the micro flow channels.
  • the present integrated, monolithic structure also houses several micro magnets that are located alongside of membranes that serve as shut off valves for the micro flow channels.
  • the battery operated pump module with flow control logic consists of a cylindrical structure that includes a battery, a programmable IC chip, and several electromagnets.
  • the pump module is hermetically seated and is assembled with the drug reservoir prior to encapsulation within the protective housing.
  • the pumping dynamics will determine the flow rate within each micro flow channel and the total delivery rate is determined by the number of micro flow channels.
  • the implantable drug delivery system can provide controlled release, pulsatile delivery, or programmable delivery (such as delivery only at certain times of day, or only on certain days).
  • the size of the drug reservoir will determine the total amount of drug delivered and the duration of such delivery.
  • one wall of the reservoir collapses due to the vacuum that is created and takes up the space formerly occupied by the expelled amount of drug, in a manner similar to a bag of IV solution.
  • the exit of the micro channels could also be terminated with a micro bore tubing which extends from the device, acting as a catheter for delivery to a site that may be hard or undesirable to access with the implantable drug delivery system (ie: a site where it is difficult to position the implantable drug delivery system).
  • a micro bore tubing which extends from the device, acting as a catheter for delivery to a site that may be hard or undesirable to access with the implantable drug delivery system (ie: a site where it is difficult to position the implantable drug delivery system).
  • the implantable drug delivery system described above could also optionally be positioned external to the body and connected by way of a micro bore catheter to deliver the drug to specific site within the body.
  • FIGS. 3, 4 and 5 illustrate an exemplary system of operation of the present device.
  • a plurality of electromagnets EL 1 , EL 2 and EL 3 are provided.
  • electromagnets EL 1 , EL 2 and EL 3 are energized (under control of the IC Circuit of FIG. 1 and with power from the battery of FIG. 1 ) magnets M 1 , M 2 and M 3 move in radial directions D 1 , as shown.
  • the electromagnets EL 1 , EL 2 and EL 3 are activated in sequence ( FIG. 5 shows only EL 3 activated, pushing M 3 in direction D 1 , thereby pinching off flow through the flow channel passing from the drug reservoir into the patient's body such that the drug is peristaltically pumped through the flow channel into the patient's body.
  • peristaltic pumping can be achieved by magnetic actuation (as illustrated in FIGS. 1 , 3 , 4 and 5 , and also by pneumatic actuation, as described in U.S. Patent Applications Ser. No. 60/186856, filed Mar. 3, 2000; 60/147,199, filed Aug. 3, 1999; 60/141503, filed Jun. 28, 1999 and Attorney Docket No. 20174-000230, filed Jun. 27, 2000.
  • pneumatic actuation at least 3 control channels (which are disposed adjacent the flow channel, crossing over the flow channel such that an elastomeric membrane disposed therebetween is deflected into the flow channel when the control channel(s) are pressurized) can also be used to peristaltically pump fluid through the flow channel.
  • electrostatic actuation is also contemplated.
  • opposite electroded surfaces E 1 and E 2 may be energized such that they repel one another, and thereby move apart from one another, causing E 1 to deflect into the flow channel.
  • the present structure preferably comprises a multi-layer elastomeric block, with a portion of the elastomeric block comprising a membrane which either separates the control channel from the flow channel, or separates a portion of the elastomeric block in which a magnet M or an electroded surface E, thereby permitting movement of the portion of the block comprising magnet M or an electroded surface E into the flow channel.
  • a monolithic microfabricated pump/valve system can be used to deliver a medicinal agent through the stratum corneum of the skin, akin to a transdermal patch.
  • the present system is placed at an external location on the patient's body and the system delivers drugs directly to the surface of the patient. The drug(s) then diffuse into the patient's body through the stratum corneum.
  • Various optional techniques are available to enhance the transport rate through the skin barrier. These include, for example, the use of permeation enhancers and/or the disruption of the stratum corneum by mechanical or other means.
  • the present transdermal delivery system can also be used to meter precise amounts of a drug for deliver at a pre-determined rate and/or delivery profile. This rate of delivery could be modified as desired.
  • An exemplary embodiment of such a device would be similar to the implantable device shown in FIG. 1 , however, the aspect ratio could be such that the diameter of the cylinder is instead much larger than the height of the device such that the system can be easily worn like a transdermal patch on the skin.
  • FIG. 2 illustrates a transdermal body fluid sampling device in accordance with the present invention.
  • a transdermal body fluid sampling device in accordance with the present invention.
  • One exemplary use of such a device would be to measure glucose in interstitial body fluids to determine when and if to deliver insulin in diabetes management.
  • a thin gel layer is located underneath an array of micro channels that lead to a single flow channel (which is in turn connected to the drug reservoir). Within this larger channel is a sensor that measures the amount of glucose in interstitial body fluid.
  • the larger flow channel Upon actuation, the larger flow channel will create a vacuum that will assist the flow of IBF into the array of micro channels and then allow it to flow past a sensor located inside the larger channel.
  • the sensor will measure the amount of glucose and display the results.
  • the present invention also comprises systems which combine a sampling system with a drug delivery system (and link them to provide sensing-loop controlled drug delivery). In the case of insulin delivery, for example, this would be a tremendous benefit in diabetes management.
  • any suitable drug may be dispensed.
  • This list of drugs includes, but is not limited to the following:

Abstract

An implantable drug delivery system has a housing, a collapsible reservoir, a microfabricated flow channel, and at least one magnet. The collapsible reservoir is disposed in the housing. The microfabricated flow channel is connected at one end to the collapsible reservoir and opens at an external surface of the housing. The magnet is disposed within the housing adjacent a membrane defining the flow channel and is movable in response to a magnetic force to deflect the membrane into the flow channel for inhibiting drug flow from the collapsible reservoir to the external surface of the housing, and for pumping drug flow from the collapsible reservoir to the external surface of the housing.

Description

  • An advantage of having a collapsible drug reservoir is that, as the drug is pumped out of the reservoir (by the present microfabricated pump/vale system), a negative pressure is not created in the drug reservoir.
  • The drug reservoir and micro flow channels are created as an integrated, monolithic structure using soft lithography front any of the elastomers that are compatible with a specific drug, and according to any of the systems set forth in U.S. Patent Application Ser. No. 60/186856, filed Mar. 3, 2000; 60/147199, filed Aug. 3, 1999; 60/141503, filed Jun. 28, 1999 and Attorney Docket No. 20174-000230, filed Jun. 27, 2000.
  • The delivery end of the micro channels (through which the drug is pumped from the drug reservoir to the surface of the device) may be terminated with any suitable valve structure, for example a duck bill narrow diameter valve or a flap valve. These valves will normally remain closed and will open under the fluid pressure of the drug during expulsion from the micro flow channels. The present integrated, monolithic structure also houses several micro magnets that are located alongside of membranes that serve as shut off valves for the micro flow channels.
  • The battery operated pump module with flow control logic consists of a cylindrical structure that includes a battery, a programmable IC chip, and several electromagnets. The pump module is hermetically seated and is assembled with the drug reservoir prior to encapsulation within the protective housing. The pumping dynamics will determine the flow rate within each micro flow channel and the total delivery rate is determined by the number of micro flow channels.
  • Depending on the program logic, the implantable drug delivery system can provide controlled release, pulsatile delivery, or programmable delivery (such as delivery only at certain times of day, or only on certain days). The size of the drug reservoir will determine the total amount of drug delivered and the duration of such delivery. In a preferred aspect of the present invention, as the drug is depleted from the reservoir, one wall of the reservoir collapses due to the vacuum that is created and takes up the space formerly occupied by the expelled amount of drug, in a manner similar to a bag of IV solution.
  • In optional aspects of the invention, the exit of the micro channels could also be terminated with a micro bore tubing which extends from the device, acting as a catheter for delivery to a site that may be hard or undesirable to access with the implantable drug delivery system (ie: a site where it is difficult to position the implantable drug delivery system).
  • The implantable drug delivery system described above could also optionally be positioned external to the body and connected by way of a micro bore catheter to deliver the drug to specific site within the body.
  • FIGS. 3, 4 and 5 illustrate an exemplary system of operation of the present device. As seen in FIG. 3, (and the breakaway close-up view of FIG. 4) a plurality of electromagnets EL1, EL2 and EL3 are provided. When electromagnets EL1, EL2 and EL3 are energized (under control of the IC Circuit of FIG. 1 and with power from the battery of FIG. 1) magnets M1, M2 and M3 move in radial directions D1, as shown.
  • In a preferred aspect of the present invention, the electromagnets EL1, EL2 and EL3 are activated in sequence (FIG. 5 shows only EL3 activated, pushing M3 in direction D1, thereby pinching off flow through the flow channel passing from the drug reservoir into the patient's body such that the drug is peristaltically pumped through the flow channel into the patient's body.
  • It is to be understood that peristaltic pumping can be achieved by magnetic actuation (as illustrated in FIGS. 1, 3,4 and 5, and also by pneumatic actuation, as described in U.S. Patent Applications Ser. No. 60/186856, filed Mar. 3, 2000; 60/147,199, filed Aug. 3, 1999; 60/141503, filed Jun. 28, 1999 and Attorney Docket No. 20174-000230, filed Jun. 27, 2000. In an example of pneumatic actuation, at least 3 control channels (which are disposed adjacent the flow channel, crossing over the flow channel such that an elastomeric membrane disposed therebetween is deflected into the flow channel when the control channel(s) are pressurized) can also be used to peristaltically pump fluid through the flow channel. In addition to pneumatic and magnetic actuation, electrostatic actuation is also contemplated. For example, as shown in FIG. 6 (and the break away close up of FIG. 7), opposite electroded surfaces E1 and E2 may be energized such that they repel one another, and thereby move apart from one another, causing E1 to deflect into the flow channel.
  • In the various aspects of the invention in which magnets M or electroded surfaces E are used for peristaltic pumping, the present structure preferably comprises a multi-layer elastomeric block, with a portion of the elastomeric block comprising a membrane which either separates the control channel from the flow channel, or separates a portion of the elastomeric block in which a magnet M or an electroded surface E, thereby permitting movement of the portion of the block comprising magnet M or an electroded surface E into the flow channel.
  • Part II—Transdermal Delivery of Medicinal Agents
  • In another aspect of the invention, a monolithic microfabricated pump/valve system can be used to deliver a medicinal agent through the stratum corneum of the skin, akin to a transdermal patch. In this aspect of the present invention, the present system is placed at an external location on the patient's body and the system delivers drugs directly to the surface of the patient. The drug(s) then diffuse into the patient's body through the stratum corneum. Various optional techniques are available to enhance the transport rate through the skin barrier. These include, for example, the use of permeation enhancers and/or the disruption of the stratum corneum by mechanical or other means.
  • The present transdermal delivery system can also be used to meter precise amounts of a drug for deliver at a pre-determined rate and/or delivery profile. This rate of delivery could be modified as desired. An exemplary embodiment of such a device would be similar to the implantable device shown in FIG. 1, however, the aspect ratio could be such that the diameter of the cylinder is instead much larger than the height of the device such that the system can be easily worn like a transdermal patch on the skin.
  • Part III—Transdermal Body Fluid Sampling and Diagnosis
  • FIG. 2 illustrates a transdermal body fluid sampling device in accordance with the present invention. One exemplary use of such a device would be to measure glucose in interstitial body fluids to determine when and if to deliver insulin in diabetes management. In one embodiment of such a device, a thin gel layer is located underneath an array of micro channels that lead to a single flow channel (which is in turn connected to the drug reservoir). Within this larger channel is a sensor that measures the amount of glucose in interstitial body fluid.
  • Upon actuation, the larger flow channel will create a vacuum that will assist the flow of IBF into the array of micro channels and then allow it to flow past a sensor located inside the larger channel. The sensor will measure the amount of glucose and display the results.
  • The present invention also comprises systems which combine a sampling system with a drug delivery system (and link them to provide sensing-loop controlled drug delivery). In the case of insulin delivery, for example, this would be a tremendous benefit in diabetes management.
  • PART IV—Exemplary Drugs
  • In accordance with the present invention, any suitable drug may be dispensed. This list of drugs includes, but is not limited to the following:
  • Therapeutic Drugs:
  • Central Nervous System
  • Cardiovascular
  • Inner Ear
  • Oncology
  • Ocular
  • Tissue Engineering
  • Neurological
  • Inner Cranial
  • Rheumatoid Arthritis
  • Parkinson's Diseases
  • Contraception
  • Anti-Epileptics
  • Anemia
  • Diabetes
  • Multiple Sclerosis
  • Schizophrenia
  • AIDS Infections
  • Other:
  • Chemical Make-up
  • Small Molecule
  • Protein (large molecule)

Claims (12)

1.-4. (canceled)
5. A microfluidic drug delivery device, comprising
an elastomeric block having a drug reservoir disposed therein;
a flow channel in fluid connection with both the drug reservoir and the external surface of the device;
at least one valve disposed within the device for inhibiting drug flow from the reservoir to the external surface of the device.
6. The drug delivery device of claim 5 further comprising a peristaltic pump, said peristaltic pump comprising at least three control channels disposed adjacent the flow channel, the three control channels being capable of sequential activation, each collapsing the flow channel, thereby peristaltically pumping the drug through the flow channel.
7. The drug delivery device of claim 5 wherein said peristaltic pump is actuated pneumatically.
8. The drug delivery device of claim 5 wherein said peristaltic pump is actuated magnetically.
9. The drug delivery device of claim 5 wherein said peristaltic pump is actuated electrostatically.
10. The drug delivery device of claim 5 wherein the drug reservoir is collapsible.
11. The drug delivery device of claim 5 wherein the microfluidic drug delivery device is implantable.
12. The drug delivery device of claim 5 wherein the microfluidic drug delivery device is adapted to deliver a medicinal agent through the skin.
13. The drug delivery device of claim 5 adapted to deliver precise amounts of a drug for delivery at a predetermined rate.
14. The drug delivery device of claim 13 adapted to provide controlled release, pulsatile delivery, or programmable delivery of a drug.
15. The drug delivery device of claim 5 wherein the drug delivered is insulin.
US11/265,724 2002-05-13 2005-11-01 Drug delivery system Abandoned US20060129138A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/265,724 US20060129138A1 (en) 2002-05-13 2005-11-01 Drug delivery system

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38078402P 2002-05-13 2002-05-13
US10/438,282 US7059348B2 (en) 2002-05-13 2003-05-13 Drug delivery system
US11/265,724 US20060129138A1 (en) 2002-05-13 2005-11-01 Drug delivery system

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/438,282 Division US7059348B2 (en) 2002-05-13 2003-05-13 Drug delivery system

Publications (1)

Publication Number Publication Date
US20060129138A1 true US20060129138A1 (en) 2006-06-15

Family

ID=34915372

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/438,282 Expired - Fee Related US7059348B2 (en) 2002-05-13 2003-05-13 Drug delivery system
US11/265,724 Abandoned US20060129138A1 (en) 2002-05-13 2005-11-01 Drug delivery system

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/438,282 Expired - Fee Related US7059348B2 (en) 2002-05-13 2003-05-13 Drug delivery system

Country Status (1)

Country Link
US (2) US7059348B2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090275924A1 (en) * 2006-04-26 2009-11-05 Eastern Virginia Medical School Systems and Methods for Monitoring and Controlling Internal Pressure of an Eye or Body Part
WO2021243318A1 (en) * 2020-05-29 2021-12-02 Board Of Regents, The University Of Texas System Implantable intrathecal drug delivery system for chronic pain control

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221654B1 (en) 1996-09-25 2001-04-24 California Institute Of Technology Method and apparatus for analysis and sorting of polynucleotides based on size
US7214298B2 (en) * 1997-09-23 2007-05-08 California Institute Of Technology Microfabricated cell sorter
US8052792B2 (en) * 2001-04-06 2011-11-08 California Institute Of Technology Microfluidic protein crystallography techniques
US8709153B2 (en) 1999-06-28 2014-04-29 California Institute Of Technology Microfludic protein crystallography techniques
US7144616B1 (en) * 1999-06-28 2006-12-05 California Institute Of Technology Microfabricated elastomeric valve and pump systems
US7306672B2 (en) 2001-04-06 2007-12-11 California Institute Of Technology Microfluidic free interface diffusion techniques
US7459022B2 (en) 2001-04-06 2008-12-02 California Institute Of Technology Microfluidic protein crystallography
CA2721172C (en) 1999-06-28 2012-04-10 California Institute Of Technology Microfabricated elastomeric valve and pump systems
US7867763B2 (en) 2004-01-25 2011-01-11 Fluidigm Corporation Integrated chip carriers with thermocycler interfaces and methods of using the same
US20050118073A1 (en) * 2003-11-26 2005-06-02 Fluidigm Corporation Devices and methods for holding microfluidic devices
US7351376B1 (en) 2000-06-05 2008-04-01 California Institute Of Technology Integrated active flux microfluidic devices and methods
EP1334347A1 (en) 2000-09-15 2003-08-13 California Institute Of Technology Microfabricated crossflow devices and methods
EP1343973B2 (en) 2000-11-16 2020-09-16 California Institute Of Technology Apparatus and methods for conducting assays and high throughput screening
AU2002307152A1 (en) 2001-04-06 2002-10-21 California Institute Of Technology Nucleic acid amplification utilizing microfluidic devices
US7075162B2 (en) * 2001-08-30 2006-07-11 Fluidigm Corporation Electrostatic/electrostrictive actuation of elastomer structures using compliant electrodes
US7192629B2 (en) 2001-10-11 2007-03-20 California Institute Of Technology Devices utilizing self-assembled gel and method of manufacture
US8440093B1 (en) 2001-10-26 2013-05-14 Fuidigm Corporation Methods and devices for electronic and magnetic sensing of the contents of microfluidic flow channels
EP1463796B1 (en) 2001-11-30 2013-01-09 Fluidigm Corporation Microfluidic device and methods of using same
US7691333B2 (en) 2001-11-30 2010-04-06 Fluidigm Corporation Microfluidic device and methods of using same
EP1499706A4 (en) 2002-04-01 2010-11-03 Fluidigm Corp Microfluidic particle-analysis systems
US7312085B2 (en) * 2002-04-01 2007-12-25 Fluidigm Corporation Microfluidic particle-analysis systems
EP1551753A2 (en) 2002-09-25 2005-07-13 California Institute Of Technology Microfluidic large scale integration
US8220494B2 (en) * 2002-09-25 2012-07-17 California Institute Of Technology Microfluidic large scale integration
JP5695287B2 (en) 2002-10-02 2015-04-01 カリフォルニア インスティテュート オブ テクノロジー Nucleic acid analysis of microfluids
US7604965B2 (en) 2003-04-03 2009-10-20 Fluidigm Corporation Thermal reaction device and method for using the same
US20050145496A1 (en) 2003-04-03 2005-07-07 Federico Goodsaid Thermal reaction device and method for using the same
US7476363B2 (en) 2003-04-03 2009-01-13 Fluidigm Corporation Microfluidic devices and methods of using same
US8828663B2 (en) 2005-03-18 2014-09-09 Fluidigm Corporation Thermal reaction device and method for using the same
US7666361B2 (en) 2003-04-03 2010-02-23 Fluidigm Corporation Microfluidic devices and methods of using same
CA2526368A1 (en) * 2003-05-20 2004-12-02 Fluidigm Corporation Method and system for microfluidic device and imaging thereof
SG145697A1 (en) * 2003-07-28 2008-09-29 Fluidigm Corp Image processing method and system for microfluidic devices
US7413712B2 (en) 2003-08-11 2008-08-19 California Institute Of Technology Microfluidic rotary flow reactor matrix
US7407799B2 (en) 2004-01-16 2008-08-05 California Institute Of Technology Microfluidic chemostat
JP4911722B2 (en) 2004-06-07 2012-04-04 フルイディグム コーポレイション Optical lens system and method for microfluidic devices
JP2008522795A (en) * 2004-12-03 2008-07-03 カリフォルニア インスティチュート オブ テクノロジー Microfluidic device with chemical reaction circuit
WO2006060748A2 (en) 2004-12-03 2006-06-08 California Institute Of Technology Microfluidic sieve valves
WO2006127191A2 (en) 2005-04-20 2006-11-30 Fluidigm Corporation Analysis engine and database for manipulating parameters for fluidic systems on a chip
US7637892B2 (en) * 2005-05-10 2009-12-29 Palyon Medical (Bvi) Limited Variable flow infusion pump system
US8114055B2 (en) * 2005-05-10 2012-02-14 Palyon Medical (Bvi) Limited Implantable pump with infinitely variable resistor
US8915893B2 (en) 2005-05-10 2014-12-23 Palyon Medical (Bvi) Limited Variable flow infusion pump system
US8211060B2 (en) 2005-05-10 2012-07-03 Palyon Medical (Bvi) Limited Reduced size implantable pump
US20070054293A1 (en) * 2005-08-30 2007-03-08 California Institute Of Technology Microfluidic chaotic mixing systems and methods
EP1938101A2 (en) * 2005-09-13 2008-07-02 Fluidigm Corporation Microfluidic assay devices and methods
US9067047B2 (en) * 2005-11-09 2015-06-30 The Invention Science Fund I, Llc Injectable controlled release fluid delivery system
US7815868B1 (en) 2006-02-28 2010-10-19 Fluidigm Corporation Microfluidic reaction apparatus for high throughput screening
US20080140057A1 (en) 2006-03-09 2008-06-12 Searete Llc, A Limited Liability Corporation Of State Of The Delaware Injectable controlled release fluid delivery system
US8828661B2 (en) 2006-04-24 2014-09-09 Fluidigm Corporation Methods for detection and quantification of nucleic acid or protein targets in a sample
US8055034B2 (en) 2006-09-13 2011-11-08 Fluidigm Corporation Methods and systems for image processing of microfluidic devices
WO2008067552A2 (en) * 2006-11-30 2008-06-05 Fluidigm Corporation Method and apparatus for biological sample analysis
US8157434B2 (en) * 2007-01-19 2012-04-17 Fluidigm Corporation High efficiency and high precision microfluidic devices and methods
US8016260B2 (en) 2007-07-19 2011-09-13 Formulatrix, Inc. Metering assembly and method of dispensing fluid
BRPI0816393A2 (en) 2007-09-07 2015-03-03 Fluidigm Corp METHOD FOR DETERMINING THE NUMBER OF COPIES REGARDING A TARGET POLINUCLEOTIDE SEQUENCE IN A GENOME OF AN INDIVIDUAL
US8152136B2 (en) * 2007-11-26 2012-04-10 The Hong Kong Polytechnic University Polymer microvalve with actuators and devices
US8986253B2 (en) 2008-01-25 2015-03-24 Tandem Diabetes Care, Inc. Two chamber pumps and related methods
WO2009100449A1 (en) 2008-02-08 2009-08-13 Fluidigm Corporation Dynamic array assay methods
US20090259176A1 (en) * 2008-04-09 2009-10-15 Los Gatos Research, Inc. Transdermal patch system
CN102056838B (en) 2008-04-11 2013-07-03 弗卢丁公司 Microfluidic device and methods
WO2010011852A1 (en) 2008-07-25 2010-01-28 Fluidigm Corporation Method and system for manufacturing integrated fluidic chips
WO2010017210A1 (en) 2008-08-07 2010-02-11 Fluidigm Corporation Microfluidic mixing and reaction systems for high efficiency screening
US8408421B2 (en) 2008-09-16 2013-04-02 Tandem Diabetes Care, Inc. Flow regulating stopcocks and related methods
EP2334234A4 (en) 2008-09-19 2013-03-20 Tandem Diabetes Care Inc Solute concentration measurement device and related methods
US8058630B2 (en) 2009-01-16 2011-11-15 Fluidigm Corporation Microfluidic devices and methods
US8100293B2 (en) 2009-01-23 2012-01-24 Formulatrix, Inc. Microfluidic dispensing assembly
US8551787B2 (en) * 2009-07-23 2013-10-08 Fluidigm Corporation Microfluidic devices and methods for binary mixing
WO2011014704A2 (en) 2009-07-30 2011-02-03 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
SG169918A1 (en) 2009-10-02 2011-04-29 Fluidigm Corp Microfluidic devices with removable cover and methods of fabrication and application
CA2782181A1 (en) 2009-11-30 2011-06-03 Fluidigm Corporation Microfluidic device regeneration
US9353406B2 (en) 2010-10-22 2016-05-31 Fluidigm Corporation Universal probe assay methods
US9168531B2 (en) 2011-03-24 2015-10-27 Fluidigm Corporation Method for thermal cycling of microfluidic samples
US9644231B2 (en) 2011-05-09 2017-05-09 Fluidigm Corporation Nucleic acid detection using probes
CN108342453A (en) 2011-05-09 2018-07-31 富鲁达公司 Detection of nucleic acids based on probe
US8568360B2 (en) 2011-12-28 2013-10-29 Palyon Medical (Bvi) Limited Programmable implantable pump design
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
US9555186B2 (en) 2012-06-05 2017-01-31 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
JP6365810B2 (en) * 2013-04-18 2018-08-01 ニプロ株式会社 Subcutaneous implantable port
US10152529B2 (en) 2013-08-23 2018-12-11 Elwha Llc Systems and methods for generating a treatment map
US9557331B2 (en) 2013-08-23 2017-01-31 Elwha Llc Systems, methods, and devices for assessing microbiota of skin
WO2015027055A1 (en) * 2013-08-23 2015-02-26 Elwha Llc Systems, methods, and devices for delivering treatment to a skin surface
US10010704B2 (en) 2013-08-23 2018-07-03 Elwha Llc Systems, methods, and devices for delivering treatment to a skin surface
US9805171B2 (en) 2013-08-23 2017-10-31 Elwha Llc Modifying a cosmetic product based on a microbe profile
US9811641B2 (en) 2013-08-23 2017-11-07 Elwha Llc Modifying a cosmetic product based on a microbe profile
CN110063836A (en) * 2014-04-23 2019-07-30 塞罗斯医学有限责任公司 Vacuum aided drug delivery device
US11351347B2 (en) 2014-04-23 2022-06-07 Vacu-Site Medical, Inc. Vacuum-assisted drug delivery device and method
WO2019068136A1 (en) * 2017-10-03 2019-04-11 University Of Wollongong A device and a method for using a device to receive and/or deliver a substance in vivo

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4013074A (en) * 1974-06-21 1977-03-22 Siposs George G Implantable medication-dispensing device
US6408878B2 (en) * 1999-06-28 2002-06-25 California Institute Of Technology Microfabricated elastomeric valve and pump systems
US6640137B2 (en) * 2002-03-15 2003-10-28 Biomed Solutions Llc Biothermal power source for implantable devices

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4373527B1 (en) * 1979-04-27 1995-06-27 Univ Johns Hopkins Implantable programmable medication infusion system
US5665070A (en) * 1995-01-19 1997-09-09 I-Flow Corporation Infusion pump with magnetic bag compression
EP1183059A1 (en) * 1999-06-08 2002-03-06 Medical Research Group, Inc. Method and apparatus for infusing liquids using a chemical reaction in an implanted infusion device

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4013074A (en) * 1974-06-21 1977-03-22 Siposs George G Implantable medication-dispensing device
US6408878B2 (en) * 1999-06-28 2002-06-25 California Institute Of Technology Microfabricated elastomeric valve and pump systems
US6640137B2 (en) * 2002-03-15 2003-10-28 Biomed Solutions Llc Biothermal power source for implantable devices

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090275924A1 (en) * 2006-04-26 2009-11-05 Eastern Virginia Medical School Systems and Methods for Monitoring and Controlling Internal Pressure of an Eye or Body Part
US9381301B2 (en) * 2006-04-26 2016-07-05 Eastern Virginia Medical School Systems and methods for monitoring and controlling internal pressure of an eye or body part
WO2021243318A1 (en) * 2020-05-29 2021-12-02 Board Of Regents, The University Of Texas System Implantable intrathecal drug delivery system for chronic pain control

Also Published As

Publication number Publication date
US20050197652A1 (en) 2005-09-08
US7059348B2 (en) 2006-06-13

Similar Documents

Publication Publication Date Title
US20060129138A1 (en) Drug delivery system
EP1512422B1 (en) Implantable pump with adjustable flow rate
EP3030286B1 (en) Conformable patch pump
US6454759B2 (en) Microfabricated injectable drug delivery system
EP1888144B1 (en) Implantable infusion device with multiple controllable fluid outlets
EP2263719B1 (en) Multireservoir implantable drug delivery pumps
US9381299B2 (en) Implantable drug delivery devices
AU722943B2 (en) Transcorneal drug-release system
Meng et al. MEMS-enabled implantable drug infusion pumps for laboratory animal research, preclinical, and clinical applications
US8308686B2 (en) MEMS device and method for delivery of therapeutic agents
US20140194851A1 (en) Flow Actuated Valve for Implantable Drug Delivery Device
Chappel Implantable drug delivery devices
US20030229337A1 (en) Implantable pressure-activated micro-valve
Forouzandeh et al. A modular microreservoir for active implantable drug delivery
Gao et al. Controlled drug delivery using microdevices
US20080152510A1 (en) Valve for controlling flow of a primary fluid
Sheybani et al. Micro/Nano Devices for Drug Delivery
Ullah et al. Current Trends in MEMS Drug Delivery Techniques
AU2015207890B2 (en) Hydraulically actuated pump for long duration medicament administration
WO2009069063A1 (en) Implantable therapeutic substance delivery device
JPH0984881A (en) In-body burried-type dosing device

Legal Events

Date Code Title Description
AS Assignment

Owner name: FLUIDIGM CORPORATION - A DELAWARE CORPORATION, CAL

Free format text: REINCORPORATION ASSIGNMENT;ASSIGNOR:FLUIDIGM CORPORATION - A CALIFORNIA CORPORATION;REEL/FRAME:019899/0313

Effective date: 20070928

Owner name: FLUIDIGM CORPORATION - A DELAWARE CORPORATION,CALI

Free format text: REINCORPORATION ASSIGNMENT;ASSIGNOR:FLUIDIGM CORPORATION - A CALIFORNIA CORPORATION;REEL/FRAME:019899/0313

Effective date: 20070928

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION